MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by targeting a mRNA for degradation or translational repression. Not surprisingly, aberrant miRNA expression can cause disease, in particular cancers. Herein, we propose a series of investigations to explore the therapeutic potential of compounds that bind a miRNA precursor associated with breast cancer and inhibit its biogenesis in breast cancer cells. These compounds were developed as a direct result of our currently funded R01 grant (R01- GM097455) in which we proposed to develop computational methods to design small molecules that avidly and selectively bind miRNA precursors. These studies have the potential to advance new anti-cancer therapies to the clinic and to enable development of general strategies to target miRNAs that cause other diseases such as Hepatitis C infections, Alzheimer's disease, and heart disease, among others. Our parent R01 grant proposes to: (i) establish a computational approach to identify lead small molecules for a desired RNA target using a database of RNA motif-small molecule interactions and to identify novel RNA targets from transcriptomes;and (ii) use these computational tools to identify lead small molecules that bind human miRNAs and evaluate them for inhibiting biogenesis in mammalian cell lines. Indeed, this approach was employed to rationally design a small molecule that selectively binds an oncogenic miRNA precursor, miR- 96, and inhibits its biogenesis in breast cancer cells. Importantly, miRNA profiling studies reveal that our small molecule is more selective than an antagomir, the state-of-the-art miRNA targeting modality! Thus, this small molecule is an exemplary case to push forward into animal models of cancer and test the hypothesis that small molecules can indeed drug "undruggable" RNA targets.
The Specific Aims are:
Aim 1 : Evaluate the therapeutic potential of our designed pri-miR-96 small molecule in models of triple negative and metastatic breast cancer.
Aim 2 : Validate in vivo targets, compound selectivity and mechanism of action of our designer compounds. Previously, our group has shown that small molecules can be designed to react with RNA targets in live cells. This covalent approach significantly improves bioactivity (>2500-fold) and can be used to validate the cellular targets of small molecules.
Aim 3 : Evaluate a dimeric small molecule that simultaneously binds the Drosha processing site and an adjacent internal loop in pri-miR-96. We have designed a potent dimeric small molecule that targets pri-miR-96 in vitro (~500-fold more potent than our lead monomeric small molecule). We will evaluate the therapeutic potential of this compound in MDA-MB-231 breast cancer cells and metastatic and drug-resistant variants, using orthotopic xenograft models.

Public Health Relevance

We have designed a small molecule that binds an oncogenic microRNA and inhibits its function in breast cancer cells. We propose to determine the therapeutic potential of this compound and optimize it for bioactivity using two methods established in our laboratory. These studies could result in new cancer therapeutics and a general strategy to target RNAs that cause cancer and other diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
3R01GM097455-03S1
Application #
8761317
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Preusch, Peter
Project Start
2012-04-05
Project End
2016-03-31
Budget Start
2014-07-01
Budget End
2015-03-31
Support Year
3
Fiscal Year
2014
Total Cost
$269,325
Indirect Cost
$126,825
Name
Scripps Florida
Department
Type
DUNS #
148230662
City
Jupiter
State
FL
Country
United States
Zip Code
33458
Su, Zhaoming; Zhang, Yongjie; Gendron, Tania F et al. (2014) Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83:1043-50
Disney, Matthew D; Yildirim, Ilyas; Childs-Disney, Jessica L (2014) Methods to enable the design of bioactive small molecules targeting RNA. Org Biomol Chem 12:1029-39
Velagapudi, Sai Pradeep; Disney, Matthew D (2014) Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor. Chem Commun (Camb) 50:3027-9
Luo, Yiling; Disney, Matthew D (2014) Bottom-up design of small molecules that stimulate exon 10 skipping in mutant MAPT pre-mRNA. Chembiochem 15:2041-4
Velagapudi, Sai Pradeep; Gallo, Steven M; Disney, Matthew D (2014) Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat Chem Biol 10:291-7
Tran, Tuan; Childs-Disney, Jessica L; Liu, Biao et al. (2014) Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides. ACS Chem Biol 9:904-12
Disney, Matthew D (2013) Rational design of chemical genetic probes of RNA function and lead therapeutics targeting repeating transcripts. Drug Discov Today 18:1228-36